CN114334079A - Auxiliary establishment method of artificial airway and related product - Google Patents
Auxiliary establishment method of artificial airway and related product Download PDFInfo
- Publication number
- CN114334079A CN114334079A CN202111622749.6A CN202111622749A CN114334079A CN 114334079 A CN114334079 A CN 114334079A CN 202111622749 A CN202111622749 A CN 202111622749A CN 114334079 A CN114334079 A CN 114334079A
- Authority
- CN
- China
- Prior art keywords
- drug
- concentration
- target
- configuration parameter
- time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
The embodiment of the application provides an auxiliary establishing method of an artificial airway and a related product, the method includes receiving drug selection information, wherein the drug selection information is used for determining a drug, obtaining a drug metabolism model corresponding to the drug, the drug metabolism model is used for indicating a change relation between the concentration of the drug in a target area of a human body and time, obtaining a first configuration parameter of the drug, the first configuration parameter includes a first target concentration, and calculating time required for the concentration of the drug to reach the first target concentration in the target area according to the first configuration parameter and the drug metabolism model to obtain first time; the success rate of establishing the artificial airway can be improved.
Description
Technical Field
The application relates to the technical field of medicine, in particular to an auxiliary establishing method of an artificial airway and a related product.
Background
In the clinical medical treatment process for critically ill patients, patients have the condition of difficult breathing, in order to ensure the smooth respiratory tract of the patients and ensure the normal respiratory function, doctors are generally required to establish an artificial airway for the patients to assist the patients to ventilate, and the proper time for establishing the artificial airway is determined, so that the establishment of the artificial airway is the basis for successfully establishing the artificial airway.
In the current clinical application, a doctor needs to inject related anesthetic drugs into a patient before establishing an artificial airway, and the doctor judges whether the body of the patient reaches a state suitable for establishing the artificial airway according to the posture characteristics of the patient, so that the time for establishing the artificial airway is determined.
However, the method depends on subjective judgment of a doctor, and depends too much on the mastering degree and operation experience of the doctor on the anesthetic, so that the time for establishing the artificial airway is not accurately judged, and a patient may not be in a state suitable for establishing the artificial airway, thereby causing low success rate of establishing the artificial airway.
Disclosure of Invention
The embodiment of the application discloses an auxiliary establishing method of an artificial airway and a related product, which can improve the success rate of establishing the artificial airway.
In a first aspect, an embodiment of the present application discloses an auxiliary establishment method for an artificial airway, where the method includes:
receiving drug selection information, the drug selection information being used to determine a drug;
acquiring a drug metabolism model corresponding to the drug, wherein the drug metabolism model is used for indicating the change relation between the concentration of the drug in a target area of a human body and time;
acquiring a first configuration parameter of the medicine, wherein the first configuration parameter comprises a first target concentration;
and calculating the time required for the concentration of the drug to reach the first target concentration in the target region according to the first configuration parameter and the drug metabolism model to obtain a first time.
In a possible implementation manner of the first aspect, the first configuration parameter further includes a target control manner, and the target control manner includes plasma target control or effector chamber target control;
when the target control mode is the plasma target control, the target area is plasma;
when the target control method is the effector room target control, the target region is an effector room.
In one possible embodiment of the first aspect,
the first configuration parameters further comprise a target control mode, and the target control mode comprises plasma target control and effect chamber target control;
said target region is said plasma and said effector chamber, and said first target concentration comprises a first target plasma concentration and a first target effector chamber concentration;
calculating a time required for the concentration of the drug to reach the first target concentration in the target region according to the first configuration parameter and the drug metabolism model, wherein obtaining a first time includes:
calculating a time required for the concentration of the drug to reach the first target plasma concentration in the plasma based on the first configuration parameter and the drug metabolism model to obtain the first time;
or, calculating the time required for the concentration of said drug in said effector compartment to reach said first target effector compartment concentration, resulting in said first time;
alternatively, the first time is obtained by calculating the time required for the concentration of the drug to reach the first target plasma concentration and the first target effector compartment concentration in the plasma and the effector compartment.
In a possible embodiment of the first aspect, the first configuration parameters further include a first ratio concentration and a first infusion rate;
before the obtaining the first configuration parameter of the drug, the method further includes:
acquiring state information of a patient;
and determining the first ratio concentration and the first infusion rate according to the state information.
In a possible implementation manner of the first aspect, the method further includes:
calculating a change relationship of the concentration of the drug in the target region with time from the start of the drug injection based on the first configuration parameter and the drug metabolism model, and displaying the change relationship on a display.
In a possible implementation manner of the first aspect, the method further includes:
receiving configuration parameter change information of the medicines;
modifying the first configuration parameter according to the configuration parameter modification information to obtain a second configuration parameter, wherein the second configuration parameter comprises a second target concentration;
and calculating the time required for the concentration of the drug to reach the second target concentration in the target region according to the second configuration parameter and the drug metabolism model to obtain a second time.
In a possible implementation manner of the first aspect, before the receiving the configuration parameter modification information of the medication, the method further includes:
acquiring state change information of the patient, wherein the state change information is used for indicating sudden change of the physical state of the patient;
and determining the configuration parameter change information according to the state change information.
In a second aspect, an embodiment of the present application discloses an auxiliary establishing device for an artificial airway, where the device includes:
a receiving unit for receiving drug selection information, the drug selection information being used to determine a drug;
an obtaining unit, configured to obtain a drug metabolism model corresponding to the drug, where the drug metabolism model is used to indicate a change relationship between a concentration of the drug in a target region of a human body and time;
the acquiring unit is further configured to acquire a first configuration parameter of the drug, where the first configuration parameter includes a first target concentration;
and a calculating unit, configured to calculate, according to the first configuration parameter and the drug metabolism model, a time required for the concentration of the drug to reach the first target concentration in the target region, so as to obtain a first time.
In a possible embodiment of the second aspect, the first configuration parameters further include a target control mode, the target control mode includes plasma target control or effector chamber target control;
when the target control mode is the plasma target control, the target area is plasma;
when the target control method is the effector room target control, the target region is an effector room.
In a possible embodiment of the second aspect, the first configuration parameters further include a target control mode, the target control mode includes plasma target control and effector chamber target control;
said target region is said plasma and said effector chamber, and said first target concentration comprises a first target plasma concentration and a first target effector chamber concentration;
the calculating unit is specifically configured to calculate, based on the first configuration parameter and the drug metabolism model, a time required for the concentration of the drug to reach the first target plasma concentration in the plasma, and obtain the first time;
or, the calculating unit is specifically configured to calculate a time required for the concentration of the drug to reach the first target effector compartment concentration in the effector compartment, and obtain the first time;
alternatively, the calculation unit is specifically configured to calculate a time required for the concentration of the drug to reach the first target plasma concentration and the first target effector chamber concentration in the plasma and the effector chamber, and obtain the first time.
In a possible embodiment of the second aspect, the first configuration parameters further include a first ratio concentration and a first infusion rate;
the acquiring unit is further used for acquiring the state information of the patient;
the above-mentioned device still includes:
and a determining unit, configured to determine the first mixture ratio concentration and the first infusion rate according to the status information.
In a possible embodiment of the second aspect, the calculating unit is further configured to calculate a time-dependent change relationship between the concentration of the drug at the target region from the start of the drug injection according to the first configuration parameter and the drug metabolism model;
the above-mentioned device still includes:
and the display unit is used for displaying the change relation on a display.
In a possible implementation manner of the second aspect, the receiving unit is further configured to receive configuration parameter modification information of the medication;
the calculating unit is configured to calculate, according to a second configuration parameter and the drug metabolism model, a time required for the concentration of the drug to reach a second target concentration in the target region, and obtain a second time.
The above-mentioned device still includes:
and the modifying unit is used for modifying the first configuration parameter according to the configuration parameter modification information to obtain the second configuration parameter, wherein the second configuration parameter comprises the second target concentration.
In a possible implementation manner of the second aspect, the obtaining unit is further configured to obtain state change information of the patient, where the state change information indicates an abrupt change in the physical state of the patient;
the determining unit is further configured to determine the configuration parameter change information according to the state change information.
In a third aspect, an embodiment of the present application provides an electronic device, where the electronic device includes: a memory for storing a program; a processor configured to execute the program stored in the memory, and when the program is executed, the processor is configured to perform the method according to the first aspect and any one of the optional embodiments.
In a fourth aspect, the present application provides a computer-readable storage medium, where a computer program is stored, where the computer program includes program instructions, and the program instructions, when executed by a processor, cause the processor to execute the method according to the first aspect and any one of the optional embodiments.
In a fifth aspect, an embodiment of the present application provides a computer program product, where the computer program product includes: instructions or computer programs; the above-mentioned instructions or the above-mentioned computer program, when executed, cause the method as in any one of the possible embodiments of the first aspect to be implemented.
In the auxiliary establishing method of the artificial airway in the embodiment of the application, the medicine selection information is received and used for determining the medicine; acquiring a drug metabolism model corresponding to the drug, wherein the drug metabolism model is used for indicating the change relation between the concentration of the drug in a target area of a human body and time; acquiring a first configuration parameter of the medicine, wherein the first configuration parameter comprises a first target concentration; and calculating the time required for the concentration of the drug to reach the first target concentration in the target region according to the first configuration parameter and the drug metabolism model to obtain a first time. In the embodiment of the application, a corresponding drug metabolism model can be obtained according to the drug, and the time required for the drug concentration in the target region to reach the target concentration can be obtained according to the configuration parameters corresponding to the drug and the drug metabolism model, so that the onset time of the drug can be accurately predicted.
Drawings
In order to more clearly illustrate the technical solutions in the embodiments or the background art of the present application, the drawings used in the embodiments or the background art of the present application will be briefly described below.
Fig. 1 is a flowchart of an auxiliary establishing method of an artificial airway according to an embodiment of the present disclosure;
fig. 2 is a flowchart of another method for assisting in establishing an artificial airway according to an embodiment of the present disclosure;
FIG. 3 is a graph of the concentration of a drug versus time provided in accordance with an embodiment of the present application;
FIG. 4 is a graph of the concentration of another drug over time as provided in the examples of the present application;
fig. 5 is a schematic structural diagram of an auxiliary establishing apparatus for an artificial airway according to an embodiment of the present disclosure;
fig. 6 is a schematic structural diagram of an electronic device according to an embodiment of the present application.
Detailed Description
In order to make the objects, technical solutions and advantages of the present application more clear, the present application will be further described with reference to the accompanying drawings.
The terms "first" and "second," and the like in the description, claims, and drawings of the present application are used solely to distinguish between different objects and not to describe a particular order. Furthermore, the terms "comprising" and "having," as well as any variations thereof, are intended to cover non-exclusive inclusions. Such as a process, method, system, article, or apparatus that comprises a list of steps or elements is not limited to only those steps or elements listed, but may alternatively include other steps or elements not listed, or inherent to such process, method, article, or apparatus.
Reference herein to "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment can be included in at least one embodiment of the application. The appearances of the phrase in various places in the specification are not necessarily all referring to the same embodiment, nor are separate or alternative embodiments mutually exclusive of other embodiments. Those skilled in the art will explicitly and implicitly appreciate that the embodiments described herein may be combined with other embodiments.
In this application, "at least one" means one or more, "a plurality" means two or more, "at least two" means two or three and three or more, "and/or" for describing an association relationship of associated objects, which means that there may be three relationships, for example, "a and/or B" may mean: only A, only B and both A and B are present, wherein A and B may be singular or plural. The character "/" generally indicates that the former and latter associated objects are in an "or" relationship. "at least one item(s) below" or similar expressions refer to any combination of these items. For example, at least one (one) of a, b, or c, may represent: a, b, c, "a and b," a and c, "" b and c, "or" a and b and c.
In order to more clearly describe the scheme of the present invention, some knowledge related to the method for establishing an artificial airway and related products provided by the embodiments of the present application will be described first.
Artificial airway: an artificial airway is a gas passage established by placing a catheter into the trachea of a patient via the upper airway or directly into the trachea of the patient. Can guarantee that patient's air flue is unobstructed and the effective connection of establishing between physiology air flue and air or other air supplies, for effective drainage, unobstructed, mechanical ventilation of patient's air flue, treatment lung disease provide the condition, the most common artificial air flue is the trachea cannula of oral cavity or intranasal mode, needs the patient to keep sufficient sedation and the sufficient relaxation of patient's muscle, otherwise, the intubate fails easily, and intubate many times may cause certain influence to patient's health.
Drug metabolism model: the pharmacokinetics model is mainly used for quantitatively researching the processes of the medicine in the organism, such as absorption, distribution, metabolism, excretion and the like, and explaining the dynamic rule of the medicine in the organism by using mathematical principles and methods. Is the basis for determining the administration dosage and the interval time of the medicine and is used for judging whether the medicine can reach safe and effective concentration at the action part, and the concentration of the medicine at the action part dynamically changes under the influence of the in-vivo process of the medicine.
In the clinical medical treatment process for critically ill patients, patients have the condition of difficult breathing, in order to ensure the smooth respiratory tract of the patients and ensure the normal respiratory function, doctors are generally required to establish an artificial airway for the patients to assist the patients to ventilate, and the proper time for establishing the artificial airway is determined, so that the establishment of the artificial airway is the basis for successfully establishing the artificial airway.
In the current clinical application, a doctor needs to inject related anesthetic drugs into a patient before establishing an artificial airway, and the doctor judges whether the body of the patient reaches a state suitable for establishing the artificial airway according to the posture characteristics of the patient, so that the time for establishing the artificial airway is determined.
However, the method depends on subjective judgment of a doctor, and depends too much on the mastering degree and operation experience of the doctor on the anesthetic, so that the time for establishing the artificial airway is not accurately judged, and a patient may not be in a state suitable for establishing the artificial airway, thereby causing low success rate of establishing the artificial airway.
In view of the defects of the above method, the present application provides an auxiliary establishment method of an artificial airway, which may include the following steps, as shown in fig. 1:
101. drug selection information is received, the drug selection information being used to determine a drug.
The drug selection information is used to determine the drugs selected by the doctor for the patient during the clinical medical procedure, and the drugs may be classified into sedatives, analgesics, muscle relaxants, and the like according to their uses. In the process of establishing the artificial airway, the three medicines have different effects, and the sedative can be used for slightly inhibiting cerebral cortex, relieving central nervous excitability, alleviating excitement, eliminating restlessness and recovering the quiet mood of a patient; the analgesic drug mainly acts on the central nervous system or the peripheral nervous system, selectively inhibits and relieves various pains, and can relieve fear, tension and emotional pains caused by the pains; the muscle relaxing drug can relax the muscle of the patient, so that the intubation operation is convenient to carry out; the drugs commonly used in establishing artificial airways include dexmedetomidine, propofol, rocuronium bromide and the like.
102. And acquiring a drug metabolism model corresponding to the drug, wherein the drug metabolism model is used for indicating the change relation between the concentration of the drug in the target area of the human body and time.
Different said drugs, corresponding to different models of drug metabolism; the target region is an action region of the drug, and includes at least one of plasma and an effector chamber, optionally, the effector chamber may include a plurality of effector chambers on which the drug acts, and the concentration of the drug in the target region reaches a certain degree, and the corresponding drug effect of the drug, such as anesthesia, sedation, analgesia, and the like, may be exerted; the drug metabolism model can accurately indicate the change of the concentration of the drug in the target region with time during the continuous administration of the drug.
103. A first configuration parameter of the drug is obtained, the first configuration parameter including a first target concentration.
Before the patient is injected with the drug, the configuration parameters of the drug need to be configured, and the configuration parameters are different for different patients with different conditions. Under the condition that the concentration of the medicine in the target area reaches the first target concentration, the concentration of the medicine in the body of the patient reaches a concentration which is effective and does not produce toxic reaction, so that the medicine effect of the medicine can obtain better effect, and the artificial airway can be conveniently established.
In some implementations of the present application, the first configuration parameter further includes a target control mode, the target control mode including plasma target control or effector chamber target control;
when the target control mode is the plasma target control, the target area is plasma;
when the target control method is the effector room target control, the target region is an effector room.
In the drug disposition process, the target control mode is different for different types of drugs, and when the target region is the plasma, the change relationship of the concentration of the drug in the plasma with time can be calculated according to the drug metabolism model, and when the target region is the effector chamber, the change relationship of the concentration of the drug in the effector chamber with time can be calculated according to the drug metabolism model. The embodiment can be used for medicines with different target control modes, and can meet more application scenes.
In some implementations of the present application, the first configuration parameters further include a target control mode, the target control mode including plasma target control and effector chamber target control;
said target region is said plasma and said effector chamber, and said first target concentration comprises a first target plasma concentration and a first target effector chamber concentration;
calculating a time required for the concentration of the drug to reach the first target concentration in the target region according to the first configuration parameter and the drug metabolism model, wherein obtaining a first time includes:
calculating a time required for the concentration of the drug to reach the first target plasma concentration in the plasma based on the first configuration parameter and the drug metabolism model to obtain the first time;
or, calculating the time required for the concentration of said drug in said effector compartment to reach said first target effector compartment concentration, resulting in said first time;
alternatively, the first time is obtained by calculating the time required for the concentration of the drug to reach the first target plasma concentration and the first target effector compartment concentration in the plasma and the effector compartment.
Where the target regime includes the plasma target and effector compartment target, the first target concentration includes the first target plasma concentration indicative of a target concentration of the drug in plasma and the first target effector compartment concentration indicative of a target concentration of the drug in an effector compartment. In this embodiment, when the target control manner includes plasma target control and effect chamber target control, the time for the concentration of the drug to reach the first target plasma concentration or reach the first target effect chamber concentration, or reach the first target plasma concentration and reach the first target effect chamber concentration may be obtained, and the method is applicable to different drugs according to actual application conditions, can determine the onset time of the drug, and can satisfy more application scenarios for different drug target control manners.
In some implementations of the present application, the first configuration parameter further includes a first formula concentration and a first infusion rate;
before the obtaining the first configuration parameter of the drug, the method further includes:
acquiring state information of a patient;
and determining the first ratio concentration and the first infusion rate according to the state information.
The status information indicates physical information of the patient, optionally, the physical information includes other information such as height, sex, weight, age, etc., which may affect settings of the first mixture concentration and the first infusion rate, the first mixture concentration indicates a mixture concentration in the drug re-solution, the first infusion rate indicates an infusion rate of the drug during an injection process of the drug into the patient, the mixture concentration and the infusion rate of the drug are different for different patient populations, and according to the status information of the patient, appropriate drug configuration parameters may be customized for different patients, so as to improve a success rate of establishing an artificial airway.
104. And calculating the time required for the concentration of the drug to reach the first target concentration in the target region according to the first configuration parameter and the drug metabolism model to obtain a first time.
By inputting the first configuration parameter into the drug metabolism model, the time required for the concentration of the drug to reach the first target concentration, that is, the first time, is obtained by starting injection of the drug, and after the first time elapses, the optimal time for the drug to take effect is reached, and a doctor can perform intubation on a patient. Optionally, under the condition that a doctor needs to inject a plurality of different drugs into a patient, the time required for reaching the onset concentration from the beginning of injection can be obtained through the drug metabolism models corresponding to the drugs, and due to the fact that the onset times of the different drugs are different, the doctor can control the injection sequence among the different drugs, so that the times of onset of the drugs are relatively close, and the requirements of clinical application can be met.
In some implementations of the present application, the method further comprises:
calculating a change relationship of the concentration of the drug in the target region with time from the start of the drug injection based on the first configuration parameter and the drug metabolism model, and displaying the change relationship on a display.
In this embodiment, the change relationship of the concentration of the drug in the target region with time can be obtained, and the change relationship is displayed on the display, so that a doctor can be assisted in observing a proper time for establishing the artificial airway.
In some implementations of the present application, the method further comprises:
receiving configuration parameter change information of the medicines;
modifying the first configuration parameter according to the configuration parameter modification information to obtain a second configuration parameter, wherein the second configuration parameter comprises a second target concentration;
and calculating the time required for the concentration of the drug to reach the second target concentration in the target region according to the second configuration parameter and the drug metabolism model to obtain a second time.
During the injection of the above-mentioned drugs to a patient, the patient may have some abnormal conditions due to personal reasons, for example, the blood pressure, heart rate, respiration, etc. of the patient may have great changes, in which case the configuration parameters of the above-mentioned drugs need to be changed to alleviate the abnormal conditions of the patient. Obtaining the modified second configuration parameter, and recalculating the time required for the concentration of the drug to reach the second target concentration, i.e., the second time, according to the second configuration parameter and the drug metabolism model. The embodiment can be suitable for the abnormal situation of the body of the patient, can make adjustment in time, and improves the success rate of establishing the artificial airway.
In some implementations of the present application, before the receiving configuration parameter modification information for the medication, the method further comprises:
acquiring state change information of the patient, wherein the state change information is used for indicating sudden change of the physical state of the patient;
and determining the configuration parameter change information according to the state change information.
In this embodiment, the configuration parameter information is changed according to the emergency of the body state of the patient, and how to change the configuration parameter information of the medicine is determined, so that the method and the device can be applied to the situation that the body of the patient is abnormal, can make timely adjustment, and improve the success rate of establishing the artificial airway.
In the embodiment of the application, a corresponding drug metabolism model can be obtained according to the drug, and the time required for the drug concentration in the target region to reach the target concentration can be obtained according to the configuration parameters corresponding to the drug and the drug metabolism model, so that the onset time of the drug can be accurately predicted.
In the following, an application scenario of establishing an artificial airway for a patient clinically is introduced to an auxiliary establishing method of an artificial airway provided in the embodiment of the present application, as shown in fig. 2, the method includes the following steps:
201. drug selection information is received, the drug selection information being used to determine a drug.
Before establishing the artificial airway, the patient needs to be injected with a suitable anesthetic, so that the body of the patient reaches a state suitable for performing intubation, which is exemplified by other drugs such as propofol, rocuronium bromide, and dexmedetomidine, and the embodiment of the present application is not limited thereto.
202. And obtaining a drug metabolism model corresponding to the drug.
After determining the drug to be injected to the patient, a drug metabolism model corresponding to the drug may be obtained according to the drug, where the drug metabolism model is used to indicate the relationship between the concentration of the drug and the time at the target region of the human body when the drug is initially injected to the patient, and the target region of the drug is different for different drugs.
203. A first configuration parameter of the drug is obtained, the first configuration parameter including a first target concentration.
The first configuration parameter is a configuration parameter that needs to be determined before injecting the drug into the patient, and illustratively, the first configuration parameter includes a first ratio concentration, a first infusion rate, the first target concentration, and other parameters that can be determined according to the status information of the patient, and the configuration parameter is set differently for the drug due to different status of different people, and the first target concentration is a concentration at which the drug achieves an effective effect in the target region and does not cause a toxic reaction.
204. And calculating the time required for the concentration of the drug to reach the first target concentration in the target region according to the first configuration parameter and the drug metabolism model to obtain a first time.
In an embodiment of the application, according to the first configuration parameter and the drug metabolism model, a time required for the concentration of the drug to reach the first target concentration may be obtained, and after the first time elapses from the start of the injection of the drug, the first time is an onset time of the drug, and a doctor may establish an artificial airway for the patient at the onset time.
205. The time-dependent change in the concentration of the drug in the target region is calculated from the start of injection of the drug, and the change is displayed on a display.
In the embodiment of the present application, in order to more clearly display the change relationship of the concentration of the drug with time, the change relationship may be displayed on the display. Alternatively, the change relationship between the concentration of the drug and the time in the target region may be displayed in real time, or the change relationship between the concentration of the drug and the time in a future period may be displayed from the beginning of injecting the drug, which is not limited in the embodiment of the present application. For a more detailed description of the variation, please refer to fig. 3, in which fig. 3 is a graph of the variation of the concentration of a drug with time according to the embodiment of the present application.
As shown in FIG. 3, the concentration curve 301 and 302 includes a rectangular axis and two concentration curves 301 and 302, the concentration curves 301 and 302 represent the real-time variation relationship between the drug and the time, the horizontal axis of the rectangular axis is the time axis, the vertical axis is the drug concentration axis, the horizontal axis is the time (T) in seconds(s), the vertical axis is the drug concentration (C) in milligrams per milliliter (mg/ml), and the concentration curve 301 intersects the concentration axis at the point C1The concentration curve 302 intersects the concentration axis at point C2The concentration curve 301 represents the variation relationship between the concentration of the drug in the plasma and the time, the concentration curve 302 represents the variation relationship between the concentration of the drug in the effect chamber and the time, according to the horizontal axis, the 0 position represents the current time, the positive half axis and the negative half axis of the horizontal axis represent the future time point and the past time point respectively, exemplarily, the time point represented is the 30 th second in the future for the 30 position on the horizontal axis, and the time point represented is the 60 th second in the past for the-60 position on the horizontal axis, and the point C can be understood by combining the vertical coordinate1And point C2Representing the real-time concentration of the drug in plasma and in the effector compartment, respectively, at the present moment. According to this fig. 3, the doctor can observe the change of the concentration of the drug in real time and can obtain the time when the concentration of the drug reaches the preset target concentration.
For a more detailed description of the variation, please refer to fig. 4, in which fig. 4 is a graph showing the variation of the concentration and time of another drug according to the embodiment of the present application.
As shown in FIG. 4, the concentration curve 401 and 402 includes a rectangular axis and two concentration curves 401 and 402, the concentration curves 401 and 402 represent the relationship between the change of the drug and the change of the time, the horizontal axis of the rectangular axis is a time axis, the vertical axis is a drug concentration axis, the horizontal axis is time (T) in seconds(s), the vertical axis is drug concentration (C) in milligrams per milliliter (mg/ml), and the concentration curve 401 represents the change of the drug in milligrams per milliliter (mg/ml)The concentration curve 402 shows the variation of the concentration of the drug in the effector compartment with time, according to the horizontal axis, t in FIG. 40The time point at which the injection of the drug into the body is started, t1、t2、…t7Is t0At a later time point, based on a preset target concentration, the doctor can obtain the time when the concentration of the drug in the corresponding target region reaches the target concentration.
206. State change information of the patient is acquired.
The state change information includes other information such as heart rate change, blood pressure change and body temperature change of the patient, some patients may have some symptoms of stress reaction during the injection of the medicine, and in this case, it is necessary to acquire more prominent state change information of the patient.
207. And determining configuration parameter change information according to the state change information.
Based on the state change information of the patient, the physician may determine how to modify the first configuration parameters to slow the stress response of the patient.
208. And modifying the first configuration parameter according to the configuration parameter modification information to obtain a second configuration parameter, wherein the second configuration parameter comprises a second target concentration.
209. And calculating the time required for the concentration of the drug to reach the second target concentration in the target region according to the second configuration parameter and the drug metabolism model to obtain a second time.
In an embodiment of the present invention, according to the updated configuration parameters and the drug metabolism model, the time required for the concentration of the drug to reach the second target concentration in the target region can be recalculated, so as to slow down the stress response of the patient and enable the drug to achieve the expected drug effect.
According to the embodiment of the application, the drugs related to the artificial airway are selected to be established and the corresponding drug metabolism model is obtained, the appropriate drug configuration parameters are configured according to the state information of the patient, the time required by the drugs to reach the preset target concentration is obtained through the drug metabolism model, the drug configuration parameters can be reset according to the state change of the patient in the injection process, the new time required by the concentration of the drugs to reach the preset target concentration is obtained, the application method and the device are applicable to various application scenes, the individual difference of the patient is considered, and the success rate of establishing the artificial airway is improved.
The process of auxiliary establishment of an artificial airway is described below with reference to an auxiliary establishment apparatus of an artificial airway, and fig. 5 is a schematic structural diagram of an auxiliary establishment apparatus of an artificial airway provided in an embodiment of the present application. According to fig. 5, the device comprises:
a receiving unit 501, configured to receive medicine selection information, where the medicine selection information is used to determine a medicine;
an obtaining unit 503, configured to obtain a drug metabolism model corresponding to the drug, where the drug metabolism model is used to indicate a change relationship between a concentration of the drug in a target region of a human body and time;
the obtaining unit 503 is further configured to obtain a first configuration parameter of the drug, where the first configuration parameter includes a first target concentration;
a calculating unit 505, configured to calculate, according to the first configuration parameter and the drug metabolism model, a time required for the concentration of the drug to reach the first target concentration in the target region, so as to obtain a first time.
In a possible embodiment of the second aspect, the first configuration parameters further include a target control mode, the target control mode includes plasma target control or effector chamber target control;
when the target control mode is the plasma target control, the target area is plasma;
when the target control method is the effector room target control, the target region is an effector room.
In a possible embodiment of the second aspect, the first configuration parameters further include a target control mode, the target control mode includes plasma target control and effector chamber target control;
said target region is said plasma and said effector chamber, and said first target concentration comprises a first target plasma concentration and a first target effector chamber concentration;
the calculating unit 505 is specifically configured to calculate, according to the first configuration parameter and the drug metabolism model, a time required for the concentration of the drug to reach the first target plasma concentration in the plasma, and obtain the first time;
alternatively, the calculating unit 505 is specifically configured to calculate a time required for the concentration of the drug to reach the first target effector compartment concentration in the effector compartment, and obtain the first time;
alternatively, the calculating unit 505 is specifically configured to calculate the time required for the concentration of the drug to reach the first target plasma concentration and the first target effector compartment concentration in the plasma and the effector compartment, and obtain the first time.
In a possible embodiment of the second aspect, the first configuration parameters further include a first ratio concentration and a first infusion rate;
the acquiring unit 503 is further configured to acquire status information of the patient;
the above-mentioned device still includes:
a determining unit 504, configured to determine the first mixture ratio concentration and the first infusion rate according to the status information.
In a possible implementation manner of the second aspect, the calculating unit 505 is further configured to calculate a time-dependent change relationship between the concentration of the drug in the target region from the beginning of the drug injection according to the first configuration parameter and the drug metabolism model;
the above-mentioned device still includes:
and the display unit is used for displaying the change relation on a display.
In a possible implementation manner of the second aspect, the receiving unit 501 is further configured to receive configuration parameter modification information of the medication;
the calculating unit 505 is configured to calculate a time required for the concentration of the drug to reach a second target concentration in the target region according to a second configuration parameter and the drug metabolism model, so as to obtain a second time.
The above-mentioned device still includes:
a modifying unit 502, configured to modify the first configuration parameter according to the configuration parameter modification information to obtain the second configuration parameter, where the second configuration parameter includes the second target concentration.
In a possible implementation manner of the second aspect, the obtaining unit 503 is further configured to obtain state change information of the patient, where the state change information is used for indicating an abrupt change of the physical state of the patient;
the determining unit 504 is further configured to determine the configuration parameter change information according to the state change information.
It should be understood that the above division of each unit in the partitioning apparatus is only a division of logical functions, and the actual implementation may be wholly or partially integrated into one physical entity, or may be physically separated. For example, each of the above units may be a processing element separately set up, or may be implemented by being integrated in a chip of the terminal, or may be stored in a storage element of the controller in the form of program code, and a processing element of the processor calls and executes the functions of each of the above units. In addition, the units can be integrated together or can be independently realized. The processing element may be an integrated circuit chip having signal processing capabilities. In implementation, the steps of the method or the units above may be implemented by hardware integrated logic circuits in a processor element or instructions in software. The processing element may be a general-purpose processor, such as a Central Processing Unit (CPU), or may be one or more integrated circuits configured to implement the above method, such as: one or more application-specific integrated circuits (ASICs), one or more microprocessors (DSPs), one or more field-programmable gate arrays (FPGAs), etc.
Fig. 6 is a schematic structural diagram of an electronic device according to an embodiment of the present application. As shown in fig. 6, the electronic device 600 includes a processor 601, a memory 602, and a communication interface 603; the processor 601, the memory 602, and the communication interface 603 are connected to each other by a bus.
The memory 602 includes, but is not limited to, a Random Access Memory (RAM), a read-only memory (ROM), an erasable programmable read-only memory (EPROM), or a compact disc read-only memory (CDROM), and the memory 602 is used for related instructions and data. The communication interface 603 is used for receiving and transmitting data, and may implement the functions of the receiving unit 501 and the obtaining unit 503 in fig. 5.
The processor 601 may be one or more Central Processing Units (CPUs), and in the case that the processor 601 is one CPU, the CPU may be a single-core CPU or a multi-core CPU. In particular, the processor 601 may implement the functions of the modifying unit 502, the determining unit 504 and the calculating unit 505 in fig. 5.
The processor 601 in the electronic device 600 is configured to read the program code stored in the memory 602 and execute the method for establishing an artificial airway in the foregoing embodiments.
In an embodiment of the present application, there is provided a computer-readable storage medium storing a computer program which, when executed by a processor, implements: receiving drug selection information, wherein the drug selection information is used for determining a drug, obtaining a drug metabolism model corresponding to the drug, the drug metabolism model is used for indicating a change relation between the concentration of the drug in a target area of a human body and time, obtaining a first configuration parameter of the drug, the first configuration parameter comprises a first target concentration, and calculating time required for the concentration of the drug to reach the first target concentration in the target area according to the first configuration parameter and the drug metabolism model to obtain first time.
As will be appreciated by one skilled in the art, embodiments of the present invention may be provided as a method, system, or computer program product. Accordingly, the present invention may take the form of an entirely hardware embodiment, an entirely software embodiment or an embodiment combining software and hardware aspects. Furthermore, the present invention may take the form of a computer program product embodied on one or more computer-usable storage media (including, but not limited to, disk storage, CD-ROM, optical storage, and the like) having computer-usable program code embodied therein.
The present invention is described in terms of flowcharts and/or block diagrams of methods, apparatus (systems), and computer program products according to embodiments of the invention. It will be understood that each flow and/or block of the flow diagrams and/or block diagrams, and combinations of flows and/or blocks in the flow diagrams and/or block diagrams, can be implemented by computer program instructions. These computer program instructions may be provided to a processor of a general purpose computer, special purpose computer, embedded processor, or other programmable data processing apparatus to produce a machine, such that the instructions, which execute via the processor of the computer or other programmable data processing apparatus, create means for implementing the functions specified in the flowchart flow or flows and/or block diagram block or blocks.
These computer program instructions may also be stored in a computer-readable memory that can direct a computer or other programmable data processing apparatus to function in a particular manner, such that the instructions stored in the computer-readable memory produce an article of manufacture including instruction means which implement the function specified in the flowchart flow or flows and/or block diagram block or blocks.
These computer program instructions may also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer implemented process such that the instructions which execute on the computer or other programmable apparatus provide steps for implementing the functions specified in the flowchart flow or flows and/or block diagram block or blocks.
Claims (10)
1. An auxiliary establishment method of an artificial airway, characterized in that the method comprises:
receiving drug selection information, the drug selection information being used to determine a drug;
acquiring a drug metabolism model corresponding to the drug, wherein the drug metabolism model is used for indicating the change relation between the concentration of the drug in a target area of a human body and time;
obtaining a first configuration parameter of the drug, the first configuration parameter comprising a first target concentration;
and calculating the time required for the concentration of the drug to reach the first target concentration in the target region according to the first configuration parameter and the drug metabolism model to obtain a first time.
2. The method of claim 1, wherein the first configuration parameters further comprise a target control regime, the target control regime comprising plasma target control or effector chamber target control;
in the case where the target control regime is the plasma target control, the target region is plasma;
in the case that the target control mode is the effector room target control, the target area is an effector room.
3. The method of claim 1, wherein the first configuration parameters further comprise a target control regime, the target control regime comprising plasma target control and effector chamber target control;
the target region is the plasma and the effector chamber, the first target concentration includes a first target plasma concentration and a first target effector chamber concentration;
calculating, according to the first configuration parameter and the drug metabolism model, a time required for the concentration of the drug to reach the first target concentration in the target region, and obtaining a first time includes:
calculating the time required for the concentration of the drug to reach the first target plasma concentration in the plasma according to the first configuration parameter and the drug metabolism model to obtain the first time;
or, calculating the time required for the concentration of the drug to reach the first target effector compartment concentration in the effector compartment, resulting in the first time;
alternatively, the time required for the concentration of the drug to reach the first target plasma concentration and the first target effector compartment concentration in the plasma and the effector compartment is calculated, resulting in the first time.
4. The method of any one of claims 1 to 3, wherein the first configuration parameters further comprise a first proportioning concentration and a first infusion rate;
prior to the obtaining the first configuration parameter of the medication, the method further comprises:
acquiring state information of a patient;
and determining the first proportioning concentration and the first infusion rate according to the state information.
5. The method according to any one of claims 1 to 4, further comprising:
calculating the change relation of the concentration of the drug in the target area along with the time from the beginning of the drug injection according to the first configuration parameter and the drug metabolism model, and displaying the change relation on a display.
6. The method of claim 5, further comprising:
receiving configuration parameter modification information for the medication;
modifying the first configuration parameter according to the configuration parameter modification information to obtain a second configuration parameter, wherein the second configuration parameter comprises a second target concentration;
and calculating the time required for the concentration of the drug to reach the second target concentration in the target region according to the second configuration parameter and the drug metabolism model to obtain a second time.
7. The method of claim 6, prior to said receiving configuration parameter change information for the medication, further comprising:
acquiring state change information of the patient, wherein the state change information is used for indicating sudden change of the physical state of the patient;
and determining the configuration parameter change information according to the state change information.
8. An apparatus for assisting in establishing an artificial airway, the apparatus comprising:
a receiving unit for receiving drug selection information, the drug selection information being used to determine a drug;
the acquisition unit is used for acquiring a drug metabolism model corresponding to the drug, and the drug metabolism model is used for indicating the change relation between the concentration and the time of the drug in a target area of a human body;
the acquiring unit is further used for acquiring a first configuration parameter of the medicine, wherein the first configuration parameter comprises a first target concentration;
and the calculation unit is used for calculating the time required for the concentration of the drug to reach the first target concentration in the target area according to the first configuration parameter and the drug metabolism model to obtain first time.
9. An electronic device, comprising:
a memory for storing a program;
a processor for executing the program stored in the memory, the processor being configured to perform the method of any of claims 1 to 7 when the program is executed.
10. A computer-readable storage medium, characterized in that the computer storage medium stores a computer program comprising program instructions which, when executed by a processor, cause the processor to carry out the method according to any one of claims 1 to 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111622749.6A CN114334079A (en) | 2021-12-28 | 2021-12-28 | Auxiliary establishment method of artificial airway and related product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111622749.6A CN114334079A (en) | 2021-12-28 | 2021-12-28 | Auxiliary establishment method of artificial airway and related product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114334079A true CN114334079A (en) | 2022-04-12 |
Family
ID=81014373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111622749.6A Pending CN114334079A (en) | 2021-12-28 | 2021-12-28 | Auxiliary establishment method of artificial airway and related product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114334079A (en) |
-
2021
- 2021-12-28 CN CN202111622749.6A patent/CN114334079A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Irwin et al. | Patient‐maintained propofol sedation: Assessment of a target‐controlled infusion system | |
| Gozalo-Marcilla et al. | Comparison of the influence of two different constant-rate infusions (dexmedetomidine versus morphine) on anaesthetic requirements, cardiopulmonary function and recovery quality in isoflurane anaesthetized horses | |
| CN101472631A (en) | A system for controlling administration of anaesthesia | |
| Puri et al. | Bispectral index monitoring in patients undergoing cardiac surgery under cardiopulmonary bypass | |
| WO2008057213A2 (en) | Calculation device for metabolic control of critically ill and/or diabetic patients | |
| Musk et al. | Target‐controlled infusion of propofol in dogs–evaluation of four targets for induction of anaesthesia | |
| Liu et al. | Feasibility of closed-loop titration of propofol guided by the Bispectral Index for general anaesthesia induction: a prospective randomized study | |
| Diniz et al. | Effects of dexmedetomidine on pulse pressure variation changes induced by hemorrhage followed by volume replacement in isoflurane‐anesthetized dogs | |
| US20100212666A1 (en) | System for Controlling Administration of Anaesthesia | |
| US10780239B2 (en) | Method and system for controlling patient sedation and spontaneous breathing intensity | |
| Wang et al. | Asleep-awake-asleep regimen for epilepsy surgery: a prospective study of target-controlled infusion versus manually controlled infusion technique | |
| WO2011017701A2 (en) | Methods and systems related to respiration | |
| JP2019017730A (en) | Anaesthesia auxiliary program, anaesthesia auxiliary device, anaesthesia auxiliary system and anaesthesia auxiliary method | |
| Bibian | Automation in clinical anesthesia | |
| Juern | Removing the critically ill patient from mechanical ventilation | |
| Yoldas et al. | Effects of bispectral index-controlled use of magnesium on propofol consumption and sedation level in patients undergoing colonoscopy | |
| Mayer et al. | Bispectral Index-Guided General Anesthesia in Combination with Thoracic Epidural Analgesia Reduces Recovery Time in Fast-Track Colon Surgery: Retracted | |
| CN114334079A (en) | Auxiliary establishment method of artificial airway and related product | |
| Abeles et al. | The use of conscious sedation for outpatient dermatologic surgical procedures | |
| RU2447833C1 (en) | Method for intracranial pressure control accompanying hyperbaric oxygenation in artificial pulmonary ventilation in critical patients with intracranial hemorrhage | |
| JP2016530594A (en) | Evaluation device for essential requirements of pharmacotherapy and / or paramedical care, evaluation method for executing the evaluation device, and related delivery device | |
| Yu et al. | Successful remimazolam sedation-epidural block in an older patient with severe chronic obstructive pulmonary disease: A case report | |
| Усманова et al. | ANALYSIS OF THE STAGES OF COMBINED INHALATION ANESTHESIA BASED ON THE ASSESSMENT BIS-INDEX FOR CARDIAC SURGERY IN CHILDREN | |
| Gallottini et al. | General anesthesia and dental sedation in patients with special needs: why, when and how. A clinical guide for dental practitioners | |
| Statlender et al. | Weaning from Mechanical Ventilation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |